Eli Lilly and Company’s (LLY) donanemab is not recommended for marketing authorization for the treatment of early symptomatic Alzheimer’s disease, according to an opinion released by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). Lilly will ask CHMP to re-examine. Europeans living with early symptomatic […]
Regulatory
In a randomized phase III study, Gazyva®/Gazyvaro® is the only anti-CD20 monoclonal antibody that shows a full renal response benefit.
